Abecma generated $77 million U.S. commercial revenue, growing 42% versus the second quarter Decision in September to discontinue enrollment in KarMMa-9 study results in over $80 million in anticipated cost savings over the next several years 24% reduction in operating expenses versus the second
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 4, 2024-- 2seventy bio, Inc . (Nasdaq: TSVT) will announce its third quarter 2024 financial results on Tuesday, November 12, 2024 . A conference call and webcast will be held at 8:00 a.m. ET . Participants can access the financial results conference call
2seventy and Bristol Myers Squibb discontinue enrollment in Phase 3 KarMMa-9 study Decision results in over $80 million in anticipated cost savings for 2seventy over the next several years and accelerates path to breakeven in 2025 Expanded 3L+ label drives re-acceleration in Abecma U.S.
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 29, 2024-- 2seventy bio, Inc . (Nasdaq: TSVT), announced today that members of the management team will participate in a fireside chat at the upcoming Morgan Stanley 22 nd Annual Global Healthcare Conference on September 6, 2024 at 12:20 p.m.
Following regulatory approval in the earlier line setting this quarter, Abecma generated $54 million U.S. commercial revenue and saw meaningful growth in demand Recent completion of Hemophilia A and gene editing technology sale to Novo Nordisk for up to $40 million reinforces exclusive focus on
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 5, 2024-- 2seventy bio, Inc . (Nasdaq: TSVT) will announce its second quarter 2024 financial results on Wednesday, August 7, 2024 . A conference call and webcast will be held at 8:00 a.m. ET . Participants can access the conference call live via webcast
- Divestiture Supports Company Focus on Development and Commercialization of Abecma - CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 26, 2024-- 2seventy bio, Inc . (Nasdaq: TSVT), announced today the completion of an asset purchase agreement (“APA”) by Novo Nordisk .
CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 23, 2024-- 2seventy bio, Inc . (Nasdaq: TSVT) announced today that members of the management team will present at the following upcoming investor conferences: TD Cowen 5 th Annual Oncology Innovation Summit: Insights for ASCO & EHA in a virtual fireside chat
U.S. FDA Approval of Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of Therapy; Commercial Launch Underway Completion of R&D Pipeline Divestiture to Regeneron Sets Company on Track to Focus Exclusively on Development and Commercialization of Abecma
CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 3, 2024-- 2seventy bio, Inc . (Nasdaq: TSVT) will announce its first quarter 2024 financial results on Wednesday, May 8, 2024 . A conference call and webcast will be held at 8:00 a.m. ET . Participants can access the conference call live via webcast which
